{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:41:24Z","timestamp":1790800884194,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>A previous study had established the safety and preserved of quality of life in patients with adrenal insufficiency (AI) who received prednisolone 5\u2009mg once daily at sahur (predawn) during Ramadan fasting. It has been postulated that a lower dose of prednisolone between 2 and 3\u2009mg may be sufficient for glucocorticoid replacement in this group of patients. This study aimed to assess the safety and effect on quality of life in patients with AI given prednisolone 2.5\u2009mg during Ramadan fasting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with AI on twice\u2010daily hydrocortisone, who had low or moderate risk of adrenal crisis and intended to fast, were recruited. Patients were given prednisolone 2.5\u2009mg once daily taken at sahur(predawn) and Ramadan education was given. Weight, sleep duration, physical activity, biochemical parameters and quality of life measurements (SF\u201036 questionnaire) were analysed at the end of Ramadan and compared against the patient's own baseline readings before the start of Ramadan.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 16 patients (10 men, median age 60 [50.3, 68] years) were recruited. All patients were on 15\u201320\u2009mg of hydrocortisone (in divided doses) before Ramadan, and intended to fast. Five of the participants had type 2 diabetes with low IDF\u2010DAR risk category. 18.7% of the participants were unable to complete all 29 days of fasting. Up to 62.5% of the participants reported at least one adverse event. There was a statistically significant reduction in weight (median: \u22121.6 [\u22122.5, \u22120.3]\u2009kg, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.01), systolic blood pressure (median: \u221217.0 (\u221228.8, \u22124.3) mmHg, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.01) and diastolic blood pressure (median: \u221213.0 (\u221217.8, \u22123.8) mmHg, <jats:italic>p<\/jats:italic>\u2009&lt;\u2009.01). Quality of life measures were preserved in all domains.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>With prednisolone 2.5\u2009mg daily in Ramadan fasting, more than half of the participants experienced symptoms of AI, with significant reduction in weight and blood pressure. We conclude that prednisolone 2.5\u2009mg daily is insufficient during the somewhat stressful state of Ramadan fasting. Further studies with prednisolone 3\u20134\u2009mg daily in settings with readily available prednisolone 1\u2009mg tablets may further elucidate the safety of using lower dose prednisolone in Muslim patients who fast with AI during Ramadan.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cen.15176","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T18:47:46Z","timestamp":1733942866000},"page":"103-110","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Use of Prednisolone 2.5 mg Daily During Ramadan Fasting in Patients With Adrenal Insufficiency"],"prefix":"10.1111","volume":"102","author":[{"given":"Meng\u2010Loong","family":"Mok","sequence":"first","affiliation":[{"name":"Endocrine Unit, Department of Medicine Faculty of Medicine, University Malaya Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nusrath Salma","family":"Farook","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Department of Medicine Faculty of Medicine, University Malaya Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas Ken Yoong","family":"Hee","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Department of Medicine Faculty of Medicine, University Malaya Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tharsini","family":"Sarvanandan","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Department of Medicine Faculty of Medicine, University Malaya Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan\u2010 Hziung","family":"Lim","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Department of Medicine Faculty of Medicine, University Malaya Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee\u2010Ling","family":"Lim","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Department of Medicine Faculty of Medicine, University Malaya Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shireene","family":"Vethakkan","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Department of Medicine Faculty of Medicine, University Malaya Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4993-6470","authenticated-orcid":false,"given":"Jeyakantha","family":"Ratnasingam","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Department of Medicine Faculty of Medicine, University Malaya Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2891-9-57"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042018815607925"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-016-1058-3"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2017.09.021"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1530\/EC-20-0172"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14147"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-021-02804-z"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(77)90692-0"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.3402\/ljm.v9.25391"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.4103\/1947-489X.210770"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.104958"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1710"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14999"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-27302004000500009"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1530\/EC-23-0097"},{"issue":"2","key":"e_1_2_7_17_1","first-page":"163","article-title":"Validity and Reliability of the SF\u201036: The Malaysian Context","volume":"60","author":"Sararaks S.","year":"2005","journal-title":"Medical Journal of Malaysia"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-02082-w"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X17753787"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu11020478"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02213-8"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.021560"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.5812\/asjsm.34775"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1262-3636(07)70317-8"},{"key":"e_1_2_7_25_1","unstructured":"World Health Organization.Model List of Essential Medicines: 2023. (World Health Organization \u00a02023) https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2023.02."},{"key":"e_1_2_7_26_1","unstructured":"Imperial College London. Hydrocortisone vs Prednisolone in AI (HYPER\u2010AID). (National Library of Medicine January2018) https:\/\/clinicaltrials.gov\/study\/NCT03608943."},{"key":"e_1_2_7_27_1","unstructured":"Imperial College London. Safety and Efficacy of Prednisolone in Adrenal Insufficiency Disease (PRED\u2010AID Study). (National Library of Medicine May2019) https:\/\/clinicaltrials.gov\/study\/NCT03936517."}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cen.15176","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T13:15:54Z","timestamp":1735823754000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cen.15176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1111\/cen.15176"],"URL":"https:\/\/doi.org\/10.1111\/cen.15176","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,11]]},"assertion":[{"value":"2024-08-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}